Generic vs. Brand-Name Ketamine Options

Navigating the ketamine marketplace can be confusing, and cost differences between options can be significant. Patients hear about Ketalar, generic ketamine, Spravato, and compounded ketamine — sometimes in the same conversation — without a clear picture of how these relate to each other or what differences actually matter for treatment. This article breaks down the ketamine landscape clearly.

The Ketamine Family: An Overview

Ketamine-based treatments fall into several distinct categories:

1. Ketalar — the original brand-name injectable ketamine
2. Generic ketamine hydrochloride injection — bioequivalent to Ketalar, used in IV clinics
3. Spravato (esketamine) — FDA-approved nasal spray containing only the S-enantiomer
4. Compounded ketamine tablet — custom-prepared tablets, troches, or capsules
5. Compounded injectable ketamine — sometimes used in clinic settings for IM or infusion

Ketalar: The Original Brand

Ketalar is the trade name for injectable ketamine hydrochloride, developed by Parke-Davis and approved by the FDA in 1970. It is manufactured as a solution for injection in concentrations of 10 mg/mL, 50 mg/mL, and 500 mg/mL.

Ketalar remains on the market today, though generic versions now dominate the clinical supply in most hospitals and outpatient infusion clinics.

Key facts about Ketalar:

• Racemic mixture (equal parts R- and S-ketamine)
• FDA-approved only for anesthetic use
• Manufactured under FDA cGMP standards
• Available in 20 mL and 10 mL vials
• Price varies significantly by market and procurement

Generic Ketamine Injection

After Ketalar's patent protection expired, multiple generic manufacturers entered the market with bioequivalent injectable ketamine hydrochloride. Generics are approved by the FDA through the Abbreviated New Drug Application (ANDA) process, which requires demonstration of bioequivalence to the reference listed drug (Ketalar).

Generic ketamine injection is the product most commonly used in:

• Hospital anesthesia departments
• Emergency departments
• IV ketamine infusion clinics for psychiatric treatment
• Procedure suites for sedation

Key characteristics of generic ketamine injection:

• Must meet FDA bioequivalence standards
• Same active ingredient and concentration as Ketalar
• Manufactured under cGMP (may be less rigorous than the original manufacturer)
• Significantly less expensive than Ketalar brand

When a ketamine infusion clinic talks about "IV ketamine," they are almost certainly using generic injectable ketamine, not Ketalar brand specifically.

Spravato (Esketamine): A Different Molecule

Spravato, manufactured by Janssen Pharmaceuticals, is chemically distinct from racemic ketamine. It contains only esketamine — the S(+) enantiomer of ketamine — delivered as a nasal spray.

Why Esketamine?

The two enantiomers of ketamine have different receptor binding profiles:

• S-ketamine (esketamine): Approximately 3–4 times more potent at NMDA receptors than R-ketamine
• R-ketamine: Less NMDA activity; may have different antidepressant mechanisms and a more favorable dissociative side effect profile

Janssen selected the S-enantiomer for Spravato based on its higher potency (allowing lower doses) and because isolating it enabled patent protection for an otherwise off-patent molecule.

Spravato's Approvals

• 2019: FDA approval for treatment-resistant depression (TRD) in adults, defined as failure of two or more antidepressant trials
• 2020: Additional approval for major depressive disorder with acute suicidal ideation or behavior (MDD-SI)

REMS Program

Spravato is dispensed exclusively through a Risk Evaluation and Mitigation Strategy (REMS) program. Patients cannot take Spravato at home — every dose must be administered in a certified healthcare setting with 2 hours of post-administration monitoring. This is a fundamental operational difference from ketamine tablet, which patients can often take at home.

Spravato vs. Racemic Ketamine: Is One Better?

This remains a matter of scientific debate. Spravato's FDA approval gives it a regulatory and insurance advantage. However:

• No head-to-head randomized trial has directly compared esketamine to racemic ketamine for depression
• The clinical evidence base for racemic IV ketamine is larger and more robust
• Some researchers suggest R-ketamine may have more durable antidepressant effects with less dissociation

Compounded Ketamine Tablet: The Off-Label Standard

For patients seeking oral formulations, compounded ketamine is currently the only option. Compounding pharmacies prepare ketamine in oral forms not available from manufacturers:

• Troches/lozenges: Most commonly prescribed for psychiatric use
• Tablets or capsules: Used for daily maintenance or pain protocols
• Oral solutions: Used when precise dose titration is needed or for children

Compounded ketamine tablet uses the same ketamine HCl API as Ketalar — pharmaceutical-grade powder from DEA-registered suppliers. The difference lies in formulation (converted to an oral form) and scale (compounded for individual patients rather than mass-produced).

Cost Comparison

Who Should Consider Each Option?

Generic IV ketamine (infusion clinic): Patients needing rapid acute antidepressant effect, those with severe TRD, or those who have not responded to oral forms. Best evidence base for acute depression.

Spravato: Patients with documented TRD who have insurance coverage and can comply with REMS requirements (in-clinic administration twice weekly initially). Most insurance-accessible option.

Compounded ketamine tablet: Patients seeking home-based maintenance therapy, those unable to access infusion clinics, patients on chronic pain protocols, or those who responded to IV ketamine and need maintenance between sessions.

Compounded IM ketamine: Sometimes used in clinics as a lower-cost alternative to IV with 90–95% bioavailability.

Enantiomers in Compounding

Some compounding pharmacies offer S-ketamine (esketamine) in oral formulations, distinct from Spravato. This compounded S-ketamine is not FDA-approved and does not fall under the Spravato REMS program. Its clinical advantages over compounded racemic ketamine tablet have not been established in oral formulations.

The Bottom Line

The "best" ketamine product depends entirely on the clinical context, patient needs, insurance status, and treatment goals. The key distinctions to understand are:

1. Racemic vs. esketamine: Different molecules with different receptor profiles
2. FDA-approved vs. off-label/compounded: Regulatory status affects insurance coverage and manufacturing oversight
3. Injectable vs. oral: Route determines bioavailability, onset, duration, and appropriate clinical setting
4. In-clinic vs. at-home: Spravato requires clinic administration; ketamine tablet can often be taken at home

Working with a knowledgeable prescriber who understands these distinctions will help you navigate to the option best suited to your situation.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• MedlinePlus: Esketamine Nasal Spray — National Library of Medicine drug information on FDA-approved Spravato (esketamine) for treatment-resistant depression